PlainRecalls
FDA Drug Low Class III Terminated

ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler contains 30 doses (60 blisters total), Rx Only, Manufactured by GlaxoSmithKline Durham, NC 27701. NDC 0173-0869-10

Reported: January 3, 2024 Initiated: December 12, 2023 #D-0160-2024

Product Description

ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler contains 30 doses (60 blisters total), Rx Only, Manufactured by GlaxoSmithKline Durham, NC 27701. NDC 0173-0869-10

Reason for Recall

Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification

Details

Recalling Firm
GlaxoSmithKline LLC
Units Affected
67,508 inhalers
Distribution
Distributed Nationwide in the USA and Puerto Rico.
Location
Durham, NC

Frequently Asked Questions

What product was recalled?
ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler contains 30 doses (60 blisters total), Rx Only, Manufactured by GlaxoSmithKline Durham, NC 27701. NDC 0173-0869-10. Recalled by GlaxoSmithKline LLC. Units affected: 67,508 inhalers.
Why was this product recalled?
Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification
Which agency issued this recall?
This recall was issued by the FDA Drug on January 3, 2024. Severity: Low. Recall number: D-0160-2024.